Clinical trials
Hepatocellular Carcinoma Resectable clinical trials
Below are recruiting hepatocellular carcinoma resectable clinical trials, each written for real people, not researchers. We’re tracking 205 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06911255RecruitingPhase 1/Phase 2
Testing two immunotherapy drugs with chemoembolization for liver cancer
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
SeoulAges 19 years+ - NCT06929845Recruiting
Organoid models for liver cancer study
This study uses tumor samples to create lab-grown mini-livers (organoids) to better understand liver cancer. It may help researchers learn more about the disease and develop new treatments.
RomaAges 18 years+ - NCT06950827Recruiting
Recovery after right liver surgery for liver cancer
This trial looks at how well patients do after surgery to remove the right half of the liver for a specific type of liver cancer. It helps doctors understand what leads to the best recovery after this operation.
Chengdu, SichuanAges 18 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07014150RecruitingPhase 2
Neoadjuvant combo therapy for liver cancer before surgery
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT07070076Recruiting
Y-90 therapy vs chemo infusion for liver cancer
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07122089RecruitingPhase 2
SIRT plus immunotherapy for liver cancer with portal vein clot
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
GrenobleAges 18 years+ - NCT07154082RecruitingPhase 2
Combination therapy before surgery for liver cancer
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
Wuhan, HubeiAges 18–70 - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT07239245RecruitingPhase 2
TACE plus immunotherapy for high-risk liver cancer before surgery
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT07243691Recruiting
Different infusion times of tislelizumab after liver cancer surgery
This trial tests whether giving tislelizumab (an immunotherapy drug) at different infusion times after surgery can lower the chance of liver cancer coming back in people at high risk of recurrence.
Hangzhou, ZhejiangAges 18 years+ - NCT07305428Recruiting
Making large liver tumors removable with immunotherapy and focused radiation
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
Hong KongAges 18–80 - NCT07317414RecruitingPhase 2
Beta-alanine for advanced liver cancer
This trial tests whether beta-alanine, a natural supplement, can help people with advanced liver cancer that cannot be removed by surgery. It aims to see if the treatment can slow tumor growth and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07324824RecruitingPhase 2
Sintilimab plus bevacizumab before surgery for liver cancer
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07331883RecruitingPhase 2
Sintilimab and bevacizumab after surgery for ruptured liver cancer
This trial tests whether combining two immune-based drugs (sintilimab and a bevacizumab biosimilar) after surgery can prevent liver cancer from returning in people whose tumor had ruptured. It’s for patients who have had a complete surgical removal of a ruptured hepatocellular carcinoma and are now cancer-free on imaging.
Sanming, FujianAges 18–75 - NCT04472767RecruitingPhase 2
Cabozantinib with immunotherapy plus TACE for liver cancer
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
Orange, CaliforniaAges 18 years+ - NCT07413354RecruitingPhase 2
Tislelizumab and huaier granule for advanced liver cancer
This trial tests a combination of two drugs: tislelizumab (an immunotherapy that helps your immune system attack cancer) and huaier granule (a traditional Chinese medicine extract). It is for people with advanced liver cancer that cannot be removed by surgery and who have not had other systemic treatments before.
Wuhan, HubeiAges 18 years+ - NCT06712017Enrolling by invitation
Radioactive beads treatment for liver cancer in China
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
Guangzhou, GuangdongAges 18 years+ - NCT06540508Enrolling by invitation
TACE with targeted immunotherapy for advanced liver cancer
This study looks at whether combining a liver-directed procedure called TACE with tiragolumab and targeted therapy works better for people with unresectable liver cancer that has not spread too far. Researchers will use blood and tissue tests to see how well the treatment works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05057845RecruitingPhase 2
Freezing treatment plus immunotherapy and a pill for liver cancer
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06676982RecruitingPhase 1
CAR-T cell therapy for advanced liver cancer
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
Hangzhou, ZhejiangAges 18–80 - NCT06485466RecruitingPhase 3
TACE plus Camrelizumab and Apatinib for liver cancer that can't be removed by surgery
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Chengdu, SichuanAges 18–80 - NCT06470256RecruitingPhase 1
Surgery plus targeted therapy and immunotherapy for advanced liver cancer
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
Wuhan, HubeiAges 18–75 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70
Hear when a new Hepatocellular Carcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma resectable?
- Yes. Clin2 currently lists 205 recruiting hepatocellular carcinoma resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.